ABCC2 and colorectal cancer: However, previous studies have found increased MRP2 expression and activity in oxaliplatin-resistant colorectal cancer lines in vitro, and that inhibition of MRP2 expression and activity by genetic knockdown, myricetin or other inhibitors, can reverse MRP2-mediated accumulation deficits and resistance to oxaliplatin in colorectal cancer24–26.